FMP
Longeveron Inc.
LGVN
NASDAQ
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.
1.67 USD
-0.05 (-2.99%)
About
ceo
Mr. Mohamed Wa'el Ahmed Hashad
sector
Healthcare
industry
Biotechnology
website
https://www.longeveron.com
exchange
NASDAQ
Description
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.
CIK
0001721484
ISIN
US54303L1044
CUSIP
54303L104
Address
1951 NW 7th Avenue
Phone
305 909 0840
Country
US
Employee
23
IPO Date
Feb 12, 2021
Key Executives
